Brown Capital Management LLC Sells 36,781 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Brown Capital Management LLC reduced its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 79.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,261 shares of the company’s stock after selling 36,781 shares during the period. Brown Capital Management LLC’s holdings in Omnicell were worth $404,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares during the last quarter. 1620 Investment Advisors Inc. grew its stake in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on OMCL. Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum boosted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company increased their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $50.83.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $41.82 on Thursday. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -107.23, a P/E/G ratio of 35.67 and a beta of 0.81. The firm’s 50 day simple moving average is $44.19 and its 200 day simple moving average is $37.20. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.